The aim of this study was to test the usefulness of a dialogue tool from the perspective of people with type 1 diabetes. The tool was expected to prime adults with type 1 diabetes and diabetologists to discuss relevant psychosocial aspects of diabetes during diabetes consultations. The tool (PAID-5, WHO-5 and three open-ended questions) was filled out by 40 people with type 1 diabetes three days before routine diabetes consultations and tested in consultations. Participants’ age ranged from 22 to 72 years; 39% were men; diabetes duration was four to 59 years; HbA1c: 41-59 mmol/mol (5.9-7.9%). Perceptions of using the tool and overall experience of the consultation were explored with interviews and questionnaires (CARE, PEQ). A control group of 42 people with type 1 diabetes (attending regular consultations) also filled out questionnaires about overall consultation experiences. No differences were found in age, diabetes duration, HbA1c or gender between control and intervention group. Questionnaires showed that the dialogue tool did not influence perceptions of patient-centered care (no significant between-group differences in CARE or PEQ). However, participants who experienced high diabetes distress (n=6) found the tool more relevant and useful in bringing up important and difficult topics compared to people experiencing no distress (p=0.004). Interviews showed that participants found the tool useful and relevant in preparing them for consultations and in creating an opportunity for dialogue about psychosocial aspects of diabetes. However, some participants found the tool irrelevant and the dialogues to be “mechanical.” Consultation dialogue tools seem to be a relevant way to meet the needs of people experiencing diabetes-related emotional difficulties, but these tools require diabetologists to be flexible in adapting them to the needs and wishes of the person with diabetes.


L.E. Joensen: None. A.A. Schultz: None. K.P. Madsen: None. F. Persson: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk A/S. Research Support; Self; Amgen, AstraZeneca, Novo Nordisk A/S. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk A/S. K. Nørgaard: Advisory Panel; Self; Abbott, Medtronic. Research Support; Self; Novo Nordisk A/S. Speaker’s Bureau; Self; Medtronic, Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk Inc. I. Willaing: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at